Droxidopa: A review of its use in symptomatic neurogenic orthostatic hypotension

Drugs

Volumn 75, Issue 2, 2015, Pages 197-206

  Keating, Gillian M ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; DOPA DECARBOXYLASE INHIBITOR; DROXIDOPA; EPHEDRINE; MIDODRINE; NORADRENALIN; PLACEBO; TRIPTAN DERIVATIVE;

BLOOD PRESSURE; DAILY LIFE ACTIVITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG USE; FALLING; HUMAN; META ANALYSIS; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; HYPOTENSION, ORTHOSTATIC; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; DROXIDOPA; HUMANS; HYPOTENSION, ORTHOSTATIC;

EID: 84925486577     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0342-1     Document Type: Review

References (31)

1. Freeman R, Landsberg L. The treatment of orthostatic hypotension with dihydroxyphenylserine. Clin Neuropharmacol. 1991;14(4):296-304.
2. Berger MJ, Kimpinski K. A practical guide to the treatment of neurogenic orthostatic hypotension. Can J Neurol Sci. 2014;41(2):156-63.
3. Schroeder C, Jordan J, Kaufmann H. Management of neurogenic orthostatic hypotension in patients with autonomic failure. Drugs. 2013;73(12):1267-79.
4. Lundbeck NA Ltd. NORTHERA™ (droxidopa) capsules, for oral use: US prescribing information. 2014. http://www.northera.com. Accessed 10 Dec 2014.
5. Goldstein DS. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev. 2006;24(3-4):189-203.
6. Kaufmann H. The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors. J Neural Transm. 2006;70(Suppl):477-84.
7. Goldstein DS, Holmes C, Sewell LT, et al. Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS. J Clin Pharmacol. 2011;51(1):66-74.
8. Kaufmann H. L-dihydroxyphenylserine (droxidopa): a new therapy for neurogenic orthostatic hypotension. The US experience. Clin Auton Res. 2008;18(Suppl 1):19-24.
9. Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003;108(6):724-8.
10. Goldstein DS, Holmes C, Kaufmann H, et al. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res. 2004;14(6):363-8.
11. Suzuki T, Higa S, Sakoda S, et al. Pharmacokinetic studies of oral L-threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy. Eur J Clin Pharmacol. 1982;23(5):463-8.
12. Suzuki T, Sakoda S, Ueji M, et al. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study. Neurology. 1984;34(11):1446-50.
13. Kato T, Karai N, Katsuyama M, et al. Studies on the activity of L-threo-3,4-dihydroxyphenylserine (L-DOPS) as a catecholamine precursor in the brain: comparison with that of L-DOPA. Biochem Pharmacol. 1987;36(18):3051-7.
14. US Food and Drug Administration. Droxidopa: medical review. Application number: 203202Orig1s000. 2014. http://www.fda.gov. Accessed 10 Dec 2014.
15. LeWitt P, Gorny S. Analysis of efficacy and safety outcomes in patients treated with droxidopa in combination with other drug classes [abstract no. 1294]. Mov Disord. 2012;27(Suppl 1):S425-6.
16. Kaufmann H, Oribe E, Yahr MD. Differential effect of L-threo-3,4-dihydroxyphenylserine in pure autonomic failure and multiple system atrophy with autonomic failure. J Neural Transm. 1991;3(2):143-8.
17. Mathias CJ, Senard J-M, Braune S, et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res. 2001;11:235-42.
18. Mathias CJ, Senard JM, Cortelli P. A double-blind, randomized, placebo-controlled study to determine the efficacy and safety of droxidopa in the treatment of orthostatic hypotension associated with multiple system atrophy or Parkinson's disease [abstract]. Clin Auton Res. 2007;17:272.
19. Wikstrom L, Bjerle P, Boman K. L-threo-DOPS treatment of orthostatic hypotension in Swedish patients with familial amyloidotic polyneuropathy (TTR-met30). Amyloid J Protein Fold Disord. 1996;3:162-6.
20. Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83(4):328-35.
21. Biaggioni I, Freeman R, Mathias CJ, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2014. doi: 10.1161/HYPERTENSIONAHA.114.04035.
22. Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinsons Dis. 2014;4(1):57-65.
23. Hauser RA, Isaacson S, Lisk JP, et al. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Mov Disord. 2014. doi: 10.1002/mds.26086.
24. Isaacson S, Shill H, Vernino S, et al. Durability of effect with long-term, open-label droxidopa treatment in patients with symptomatic neurogenic orthostatic hypotension (NOH 303) [abstract no. 1291]. Mov Disord. 2012;27(Suppl 1):S424-5.
25. Mathias C, Low P, Freeman R, et al. Integrated efficacy analysis of droxidopa in 2 double-blind, placebo-controlled phase 3 studies in patients with neurogenic orthostatic hypotension [abstract no. 1296]. Mov Disord. 2012;27(Suppl 1):S426.
26. Isaacson S, Hauser R, Szakacs C, et al. Droxidopa treatment impact on orthostatic symptoms and standing systolic blood pressure in patients with Parkinson's disease (PD) and symptomatic neurogenic orthostatic hypotension (NOH) [abstract]. Neurology. 2013;80(19):e203.
27. Hauser RA, Jerome LP, Schwieterman WD, et al. Impact of droxidopa treatment on falls and fall related injuries in patients with Parkinson's disease and symptomatic neurogenic orthostatic hypotension (study 306) [abstract no. 481]. Mov Disord. 2013;28(Suppl 1):S171.
28. Shill H, Vernino S, Hutchman R, et al. A multicenter, open-label study to assess the long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension (NOH 304) [abstract no. 1302]. Mov Disord. 2012;27(Suppl 1):S428.
29. Lamarre-Cliche M. Drug treatment of orthostatic hypotension because of autonomic failure or neurocardiogenic syncope. Am J Cardiovasc Drugs. 2002;2(1):23-35.
30. Upsher-Smith Laboratories Inc. Midodrine HCl tablets: US prescribing information. 2012. http://www.upsher-smith.com/. Accessed 10 Dec 2014.
31. Kaufmann H, Malamut R, Norcliffe-Kaufmann L, et al. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012;22(2):79-90.